Negative-Pressure Wound Therapy
UPDATE August 13, 3:50 p.m. EDT with comment from Smith & Nephew.
Kinetic Concepts Inc. (NYSE:KCI) says it will exit any patent infringement cases involving intellectual property it licensed from Wake Forest University, after a federal judge ruled the patents invalid last year.
The San Antonio, Texas-based company also said it’s halted royalty payments to Wake Forest for the two patents, which are related to negative pressure wound therapy technology. KCI hasn’t made any payments at all to the school this year; last year it paid out $86 million to license the IP, according to a regulatory filing.
Shares of Kinetic Concepts Inc. (NYSE:KCI) are popping on Wall Street after media reports that the company may be in play for a leveraged buyout.
Kinetic Concepts Inc. (NYSE:KCI) announced that it’s German division, KCI Medizinprodukte GmbH, landed three out of four regional contracts granted by the country’s largest state insurer, the most it could be awarded under regulation.
KCI won exclusivity as a provider of negative pressure wound therapies for evaluation of diabetic foot ulcers and post-surgical wound ruptures in those areas, which cover the southeast, southwest and west regions of Germany.
The latest round in a long-running battle over negative-pressure wound therapy patents went to Smith & Nephew plc (NYSE:SNN), after a Texas judge’s ruling that some claims in a pair of Kinetic Concepts Inc. (NYSE:KCI) patents are invalid.
Judge Royal Furgeson of the U.S. District Court for Western Texas found that the claims “would have been obvious to a person of ordinary skill in the field,” according to court documents.
A German court issues a split decision in a patent infringement lawsuit between Smith & Nephew plc and Kinetic Concepts Inc. over negative-pressure wound therapy.
A German court handed down a split decision in the long-running patent battle between Smith & Nephew plc (NYSE:SNN) and Kinetic Concepts Inc. (NYSE:KCI), over negative-pressure wound therapy, ruling that one version of Smith & Nephew’s Renasys system infringes a KCI patent but clearing another model.
After recently picking up a British court victory, Kinetic Concepts Inc. (NYSE:KCI) and Smith & Nephew Group plc (NYSE:SNN) are heading back to court in October in their long-running fight over who can legally market negative-pressure wound therapies in the United Kingdom and beyond.
A British court dealt Smith & Nephew plc (NYSE:SNN) a blow in its long-running patent infringement war with Kinetic Concepts Inc. (NYSE:KCI), ruling that two of Smith & Nephew’s Renasys negative-pressure wound therapy devices infringe patents owned by KCI.
The ruling, by Judge Richard Arnold of the
Kinetic Concepts Inc. (NYSE:KCI) is the first manufacturer to take up a new Food & Drug Administration program for labeling home-use medical devices.
The San Antonio, Texas-based device maker will voluntarily submit labeling to the FDA as part of the agency’s medical device Home Use Initiative, a 10-month pilot program for manufacturers to submit labeling of home-use medical devices to a central website.
Boston Scientific’s Kinetix guidewire promises more torque control: Boston Scientific Corp. (NYSE:BSX) announced new nitinol-based technology for guidewires, the small flexible wires used for control in percutaneous procedures. The Natick, Mass.-based medical device giant claims its new Kinetix guidewire boasts improved torque control and flexibility for getting around those tight corners in the left anterior descending artery. The improvements come from controlled flexibility in the sleeve itself, rather than from the center wire as with traditional spring coil design.